BMY vs KYTX
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. KYTX: Kyverna Therapeutics is a late-stage clinical company developing potentially curative CAR T-cell therapies for patients with severe neurologic autoimmune diseases.
Side-by-side fundamentals
| Metric | BMY | KYTX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $61.12 | $5.84 | |
| Market cap | $124.9B | $361M | |
| P/E as of 2026-10-21 | 13.46 | n/a | |
| Net margin FY2025, SEC XBRL | +14.6% | n/a | |
| ROE FY2025, SEC XBRL | +38.2% | -69.4% | BMY higher |
| ROA FY2025, SEC XBRL | +7.8% | -54.9% | BMY higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.97 | 0.15 | KYTX lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.4% | n/a | |
| Dividend yield as of 2026-09-03 | +4.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | BMY higher |
| Beta as of 2026-09-03 | 0.25 | 1.76 | |
| 1-year return as of 2026-10-21 close | +37.2% | -18.2% | BMY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.